EvolveImmune, MSK Partner on Bladder Cancer Target Study
EvolveImmune Therapeutics, an immuno-oncology company developing next-generation T cell engager biotherapeutics to overcome cancer cell resistance to current immunotherapies, today announced a translational research collaboration...